Format

Send to

Choose Destination
Indian J Cancer. 2018 Apr-Jun;55(2):125-133. doi: 10.4103/ijc.IJC_469_17.

Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.

Author information

1
Department of Radiation Oncology, Tata Medical Center, Kolkata, West Bengal, India.
2
Department of Radiotherapy Physics, Tata Medical Center, Kolkata, West Bengal, India.
3
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.
4
Department of Thoracic Surgery, Tata Medical Center, Kolkata, West Bengal, India.

Abstract

INTRODUCTION:

Radical radiotherapy (RT) with curative intent, with or without chemotherapy, is the standard treatment for inoperable, locally advanced nonsmall cell lung cancer (NSCLC).

MATERIALS AND METHODS:

We retrospectively reviewed the data for all 288 patients who presented with inoperable, locally advanced NSCLC at our institution, between May 2011 and December 2016.

RESULTS:

RT alone or sequential chemoradiotherapy (SCRT) or concurrent chemoradiotherapy (CCRT) was used for 213 patients. Median age was 64 years (range: 27-88 years). Stage-III was the biggest stage group with 189 (88.7%) patients. Most patients with performance status (PS) 0 or 1 received CCRT, whereas most patients with PS 2 received RT alone (P < 0.001). CCRT, SCRT, and RT alone were used for 120 (56.3%), 24 (11.3%), and 69 (32.4%) patients, respectively. A third of all patients (32.4%) required either volumetric-modulated arc radiotherapy (VMAT) or tomotherapy. Median follow-up was 16 months. The median progression-free survival and median overall survival (OS) were 11 and 20 months, respectively. One-year OS and 2-year OS were 67.9% and 40.7%, respectively. Patients treated using CCRT lived significantly longer with a median survival of 28 months, compared with 13 months using SCRT and RT alone (P < 0.001). On multivariate analysis, OS was significantly affected by age, stage group, treatment approach, and response to treatment.

CONCLUSION:

RT including CCRT is feasible, safe, and well tolerated in our patient population and results in survival benefits comparable with published literature. CCRT should be considered for all patients with inoperable, locally advanced NSCLC, who are fit and have good PS.

KEYWORDS:

Concurrent chemoradiotherapy; lung cancer; radical radiotherapy; sequential chemoradiotherapy; volumetric-modulated arc radiotherapy

PMID:
30604722
DOI:
10.4103/ijc.IJC_469_17
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center